-
-
-
-
-
-
-
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ G
-
-
-
-
-
-
-
Five Prime Therapeutics Reports Third Quarter 2020 Results
-
-
-
-
-
-
-
Five Prime Therapeutics (FPRX) Tops Q4 EPS by 7c
-
-
-
-
-
-
-
Five Prime Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call
-
-
-
-
-
-
-
New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group — Conso
-
-
-
-
-
-
-
Five Prime Therapeutics (FPRX) Misses Q1 EPS by 8c
-
-
-
-
-
-
-
Five Prime Therapeutics (FPRX) Misses Q3 EPS by 30c
-
1,198,655 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

